Retraction Notice: RNAi targeting CXCR4 inhibits proliferation and invasion of esophageal carcinoma cells (Diagnostic Pathology (2013) 8 (104) DOI: 10.1186/1746-1596-8-104);RNAi targeting CXCR4 inhibits proliferation and invasion of esophageal carcinoma cells

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Wang, Tao ^a,b   Mi, Yanfang ^c   Pian, Linping ^b   Gao, Ping ^a   Xu, Hong ^d   Zheng, Yuling ^a   Xuan, Xiaoyan ^c  

^a HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c ZHENGZHOU UNIVERSITY   (China)

^d Henan Tumor Institute   (China)

Author keywords

CXCR4; Esophageal carcinoma; Invasion; Proliferation

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CARCINOMA; CELL MOTION; CELL PROLIFERATION; DRUG SCREENING; ESOPHAGUS TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TIME; TUMOR CELL LINE; TUMOR INVASION; TUMOR VOLUME;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; RECEPTORS, CXCR4; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879231850     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/s13000-019-0828-y     Document Type: Erratum

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62(1):10-29. 10.3322/caac.20138, 22237781.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1990, 80:827-841.
3. Montesano R, Hollstein M, Hainant P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer 1996, 69:225-235. 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6, 8682592.
4. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761-1767. 10.1182/blood-2005-08-3182, 16269611.
5. Murdoch C. CXCR4: chemokine receptor extraordinaire. Immunol Rev 2000, 177:175-184. 10.1034/j.1600-065X.2000.17715.x, 11138774.
6. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, et al. CXCL12 (SDF1-α) - CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies. Clin Cancer Res 2011, 17:2074-2080. 10.1158/1078-0432.CCR-10-2636, 3079023, 21349998.
7. Muller A, Homey B, Soto H, Ge N, Catron D, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56. 10.1038/35065016, 11242036.
8. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, et al. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005, 65:967-971.
9. Berghuis D, Santos SJ, Baelde HJ, Taminiau AH, Egeler RM, et al. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol 2011, 223:347-357. 10.1002/path.2819, 21171080.
10. Wang L, Wang Z, Yang B, Yang Q, Wang L, et al. CXCR4 nuclear localization follows binding of its ligand SDF-1 and occurs in metastatic but not primary renal cell carcinoma. Oncol Rep 2009, 22:1333-1339.
11. Wang SC, Lin JK, Wang HS, Yang SH, Li AF, et al. Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int J Colorectal Dis 2010, 25:1185-1191. 10.1007/s00384-010-0999-1, 20607251.
12. Namlos HM, Kresse SH, Muler CR, Henriksen J, Holdhus R, et al. Global gene expression profiling of human osteosarcomas reveals metastasis-association chemokine pattern. Sarcoma 2012, 2012:639038. 3324929, 22518090.
13. Baumhoer D, Smida J, Zillmer S, Rosemann M, Atkinson MJ, et al. Strong expression of CXCL12 is associated with a favorable outcome in osteosarcoma. Mod Pathol 2012, 25:522-528. 10.1038/modpathol.2011.193, 22173290.
14. Grymula K, Tarnowski M, Wysoczynski M, Drukala J, Barr FG, et al. Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int J Cancer 2010, 127:2554-2568. 10.1002/ijc.25245, 2907445, 20162608.
15. Furusato B, Mohamed A, Uhlen M, Rhim JS. CXCR4 and cancer. Pathol Int 2010, 60:497-505. 10.1111/j.1440-1827.2010.02548.x, 20594270.
16. Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, et al. Chemokines in tumor progression and metastasis. Cancer Sci 2005, 96:317-322. 10.1111/j.1349-7006.2005.00059.x, 15958053.
17. Redjal N, Chan JA, Segal RA, Kung AL. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res 2006, 12:6765-6771. 10.1158/1078-0432.CCR-06-1372, 17121897.
18. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002, 62:1832-1837.
19. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113:4341-4351. 10.1182/blood-2008-10-186668, 2676090, 19139079.
20. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 2009, 113:4604-4613. 10.1182/blood-2008-10-185827, 19228923.
21. Li JK, Yu L, Shen Y, Zhou LS, Wang YC, et al. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J Gastroenterology 2008, 14:2308-2313.
22. Lee HJ, Kim SW, Kim HY, Li S, Yun HJ, et al. Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer. Int J Oncol 2009, 34(2):473-480.
23. Peled A, Wald O, Burger J. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 2012, 21:341-353. 10.1517/13543784.2012.656197, 22283809.
24. Hannon GJ. A interference. Nature 2002, 418:244-251. 10.1038/418244a, 12110901.
25. Tuschl T, Borkhardt A. Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy. Mol Interventions 2002, 2:158-167.
26. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, et al. Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci 2003, 11:6347-6352.
27. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, et al. Expression profiling revealsoff-target gene regulation by RNAi. Nat Biotechnol 2003, 21:635-637. 10.1038/nbt831, 12754523.
28. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet 2009, 10:94-108. 10.1038/nrg2504, 2724769, 19148191.
29. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009, 10:126-139. 10.1038/nrm2632, 19165215.
30. Czech B, Hannon GJ. Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet 2001, 12:19-31.
31. Kastenmeier A, Gonzales H, Gould JC. Robotic applications in the treatment of diseases of the esophagus. Surg Laparosc Endosc Percutan Tech 2012, 22(4):304-309. 10.1097/SLE.0b013e318258340a, 22874678.
32. Palanivelu C, Prakash A, Senthilkumar R, Senthilnathan P, Parthasarathi R, et al. minimally invasive esophagectomy: thoracoscopic mobilization of the esophagus and medi-astinal lymphadenectomy in prone position-experience of 130 patients. J Am Coll Surg 2006, 203(1):7-16. 10.1016/j.jamcollsurg.2006.03.016, 16798482.